SARMS® Myostatin, 70 mg

SARMS® Myostatin 70 mg refers to YK-11 (Myostine), a compound commonly marketed in the SARM category because of its activity at the androgen receptor and its research interest surrounding follistatin and myostatin-related muscle-growth pathways. YK-11 is structurally unusual compared with conventional non-steroidal SARMs, but its combination of androgen-receptor activity and myogenic signaling makes it particularly interesting for advanced bodybuilding and muscle-development research.

How it works

YK-11 acts as a partial androgen-receptor agonist. Research in muscle-cell models has also found that YK-11 can increase follistatin expression, a protein involved in regulating myostatin and other members of the TGF-β family.

This combination makes YK-11 particularly interesting for research focused on muscle differentiation, anabolic signaling, lean-mass development, and myostatin-associated pathways.

Proper Use and Dosage

The listed presentation contains 70 mg of YK-11.

For a 70 mg presentation:

• 5 mg = 14 administrations
• 10 mg = 7 administrations
• 15 mg = approximately 4–5 administrations
• 20 mg = 3.5 administrations
• 35 mg = 2 administrations
• 70 mg = 1 full presentation

For fitness-focused research, YK-11 is primarily associated with lean-muscle development, strength, muscular density, and myostatin/follistatin pathway research.

Benefits

SARMS® Myostatin is particularly suited to advanced research involving muscle growth, strength, anabolic signaling, and myostatin-associated pathways.

Key benefits and areas of interest include:

• Supports androgen-receptor activity
• Investigated for muscle growth
• Supports follistatin-expression research
• Relevant to myostatin-associated pathways
• Supports muscle-cell differentiation research
• Associated with lean-muscle development
• May support muscular density and hardness
• Relevant to strength-focused training research
• Supports advanced anabolic research
• Convenient 70 mg presentation

Its distinctive combination of androgen-receptor signaling and follistatin-related activity is what makes YK-11 particularly interesting compared with conventional SARMs.

Side Effects

Potential effects associated with YK-11 may include acne, changes in libido, mood changes, suppression of natural testosterone production, hair-related changes, and changes in liver enzymes or cholesterol. Human clinical safety data are limited because YK-11 has not undergone established human clinical trials.